大成生化科技(00809.HK) 发盈警,预计2024年度净收益介乎6亿至8亿元,相较上年度持续经营及已终止经营业务录得的净收益41.78亿元。主要因上年度录得一次性收益约42.85亿元。(de/d)(港股报价延迟最少十五分钟。)
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/08/20 | 中期业绩 | 无派息 |
2024/03/28 | 末期业绩 | 无派息 |
2023/08/31 | 中期业绩 | 无派息 |
2023/03/30 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.